




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 9/51		A1	(11) International Publication Number: WO 00/51572 (43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/US00/03676			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 14 February 2000 (14.02.00)			
(30) Priority Data: 09/261,151 3 March 1999 (03.03.99) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/261,151 (CIP) Filed on 3 March 1999 (03.03.99)			
(71) Applicant (for all designated States except US): NANOSYS-TEMS [US/US]; 3000 Horizon Drive, King of Prussia, PA 19406 (US).			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(72) Inventors; and			
(75) Inventors/Applicants (for US only): LIVERSIDGE, Elaine [US/US]; 258 Colwyn Terrace, West Chester, PA 19380 (US). GOTTARDY, Greta, A. [US/US]; 204 Marlbrook Lane, Lansdale, PA 19446 (US).			
(74) Agents: SCHAFER, Michele, M. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).			

(54) Title: USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS



(57) Abstract

Nanoparticulate compositions comprising an insoluble organic drug and at least one polyethylene glycol-derivatized lipid adsorbed on the surface of the drug are described. The polyethylene glycol-derivatized lipid can be a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, or a mixture thereof. The compositions have an effective average particle size of less than about 1 micron. The invention also describes methods of making and using such compositions.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS

5

FIELD OF THE INVENTION

The present invention is directed to nanoparticulate formulations of a drug having at least one polyethylene glycol (PEG)-derivatized phospholipid, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG-derivatized vitamin A, or PEG-derivatized vitamin E adsorbed on the surface of the drug as a surface stabilizer, and 10 methods of making and using such compositions.

BACKGROUND OF THE INVENTION

Nanoparticulate compositions, first described in U.S. Patent No. 5,145,684 ("the '684 patent"), are particles consisting of a poorly soluble therapeutic or diagnostic 15 agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer. The '684 patent describes the use of a variety of surface stabilizers for nanoparticulate compositions. The use of a PEG-derivatized phospholipid, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG-derivatized vitamin A, or PEG-derivatized 20 vitamin E as a surface stabilizer for nanoparticulate compositions, or any other component of such compositions, is not described by the '684 patent.

The '684 patent describes a method of screening drugs to identify useful surface stabilizers that enable the production of a nanoparticulate composition. Not all surface stabilizers will function to produce a stable, non-agglomerated nanoparticulate composition for all drugs. Moreover, known surface stabilizers may be unable to produce 25 a stable, non-agglomerated nanoparticulate composition for certain drugs. Thus, there is a need in the art to identify new surface stabilizers useful in making nanoparticulate compositions. Additionally, such new surface stabilizers may have superior properties over prior known surface stabilizers.

A. Lipids in Nanoparticulate Compositions

A lipid is an inclusive term for fats and fat-derived materials. It includes all substances which are (i) relatively insoluble in water but soluble in organic solvents (benzene, chloroform, acetone, ether, *etc.*); (ii) related either actually or potentially to fatty acid esters, fatty alcohols, sterols, waxes, *etc.*; and (iii) utilizable by the animal organism. Because lipids are relatively insoluble in water, but soluble in organic solvents, lipids are often referred to as "fat soluble," denoting substances extracted from animal or vegetable cells by nonpolar or "fat" solvents. Exemplary lipids include phospholipids (such as phosphatidylcholine, phosphatidylethanolamine, and cephalin),
5 fats, fatty acids, glycerides and glycerol ethers, sphingolipids, alcohols and waxes, terpenes, steroids, and "fat soluble" vitamins A or E, which are non-cholesterol based poorly water soluble vitamins. *Stedman's Medical Dictionary*, 25th Edition, pp. 884 (Williams & Wilkins, Baltimore, MD, 1990); *Hawley's Condensed Chemical Dictionary*,
10 11th Edition, pp. 704 (Van Nostrand Reinhold Co., New York, 1987).

15 A number of U.S. patents teach the use of a charged phospholipid, such as dimyristoyl phosphatidyl glycerol, as an auxiliary surface stabilizer for nanoparticulate compositions. *See e.g.*, U.S. Patent No. 5,834,025 for "Reduction of Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions"; U.S. Patent No. 5,747,001 for "Aerosols Containing Beclomethasone Nanoparticle
20 Dispersions"; and U.S. Patent No. 5,718,919 for "Nanoparticles Containing the R(-)Enantiomer of Ibuprofen."


Other U.S. patents describe the use of a charged phospholipid, such as diacylphosphatidyl glycerol or dimyristoyl phosphatidyl glycerol, as a cloud point modifier for the surface stabilizer of a nanoparticulate composition to prevent particle
25 aggregation during steam heat autoclaving. *See e.g.*, U.S. Patent No. 5,670,136 for "2,4,6-triiodo-5-substituted-amino-isophthalate Esters Useful as X-ray Contrast Agents for Medical Diagnostics Imaging"; U.S. Patent No. 5,668,196 for 3-amido-triiodophenyl Esters as X-ray Contrast Agents"; U.S. Patent No. 5,643,552 for "Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-ray Contrast Agents for Blood Pool and
30 Lymphatic System Imaging"; U.S. Patent No. 5,470,583 for "Method of Preparing

Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation"; and U.S. Patent No. 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation." None of these patents refer to the use of a PEG-derivatized phospholipid, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG-
5 derivatized vitamin A, or PEG-derivatized vitamin E in nanoparticulate compositions, either as a surface stabilizer, cloud point modifier, or as any other constituent of a nanoparticulate composition.

B. PEG-derivatized Lipids in Pharmaceutical Compositions

10 Liposomes, or vesicles composed of single or multiple phospholipid bilayers, have been investigated as possible carriers for drugs. Unmodified liposomes tend to be taken up in the liver and spleen. For drugs targeted to these areas, unmodified liposomes are useful drug adjuvants. However, often the liver and spleen *are not* the target areas for drug delivery. This affinity for the liver and spleen limits the
15 effectiveness of liposome-encapsulated drugs and complicates dosing. Kimelberg et al., "Properties and Biological Effects of Liposomes and Their Uses in Pharmacology and Toxicology," *CRC Crit. Rev. Toxicol.*, 6:25-79 (1978); and Allen et al., "Stealth®
Liposomes: An Improved Sustained Release System For 1-beta-D-arabinofuranosyl-cytosine," *Cancer Res.*, 52:2431-2439 (1992). To avoid these problems, researchers
20 have studied various ways of modifying the liposome structure to prolong circulation time. Allen, *Cancer Res.*, 52:2431-2439 (1992).

It was discovered that one useful type of modified lipid contains polyethylene glycol (PEG). In its most common form PEG, also known as poly(ethylene oxide) (PEO), is a linear polymer terminated at each end with hydroxyl groups:



25 This polymer can be represented as HO-PEG-OH, where it is understood that the -PEG- symbol represents the following structural unit:




PEG is particularly useful because of its ease of preparation, relatively low cost, controllability of the molecular weight, and the ability to link to lipid by various methods. PEG is believed to act by forming a hydrophilic coat and by causing steric hindrance at the liposome surface, thus reducing liposome-serum protein interaction and 5 liposome-RES (reticuloendothelial system) cells interaction. Yuda et al., "Prolongation of Liposome Circulation Time by Various Derivatives of Polyethyleneglycols," *Biol. Pharm. Bull.*, 19:1347-1351, 1347-1348 (1996).

PEG-derivatized lipids are described in, for example, U.S. Patent No. 5,672,662 ("the '662 Patent") for "Poly(Ethylene Glycol) and Related Polymers 10 Monosubstituted with Propionic or Butanoic Acids and Functional Derivatives Thereof for Biotechnical Applications," and Yuda et al. (1996).

**1. PEG-Derivatized Lipid Drug Carriers Result in Increased
In Vivo Circulation Times of the Administered Drug**

PEG derivatized lipids or liposomes are referred to as "sterically 15 stabilized" lipids or liposomes (S-lipids or S-liposomes). Allen, "Long-circulating (sterically stabilized) liposomes for targeted drug delivery," *TiPS*, 15:215-220 (1994). PEG attracts water to the lipid surface, thus forming a hydrophilic surface on the lipid. The hydrophilic surface inhibits opsonization of the lipid by plasma proteins, leading to increased survival times of PEG-lipid in the circulation. Opsonization refers to uptake by 20 the cells of the mononuclear phagocyte system (MPS), located primarily in the liver and spleen. Because PEG-derivatized lipids evade the cells of the MPS, they are often called Stealth® lipid or liposomes. Lasic D., "Liposomes," *Am. Scientist*, 80:20-31 (1992); Papahadjopoulos et al., "Sterically Stabilized Liposomes; Pronounced Improvements in Blood Clearance, Tissue Distribution, and Therapeutic Index of Encapsulated Drugs 25 Against Implanted Tumors," *PNAS, USA*, 88:11460-11464 (1991). (Stealth® is a registered trade mark of Liposome Technology, Inc., Menlo Park, CA.)

The diagram below shows a representative PEG-liposome as compared to a conventional liposome:



PEG-lipids are highly superior over conventional lipids as they exhibit:

(1) prolonged blood residence times, (2) a decreased rate and extent of uptake into the MPS with reduced chance of adverse effects to this important host defense system, (3) dose-independent pharmakokinetics in animals and humans, and (4) the ability to cross *in vivo* biological barriers. Allen at 216; Yuda et al. at 1349-1351; Bedu-Addo et al., "Interaction of PEG-phospholipid Conjugates with Phospholipid Implications in Liposomal Drug Delivery," *Advanced Drug Delivery Reviews*, 16:235-247 (1995); and Lasic et al., "The 'Stealth' Liposome: A Prototypical Biomaterial," *Chemical Reviews*, 95:2601-2628 (1995).

For example, it has been reported that PEG-derivatized lipids can result in a great increase in the blood circulation lifetime of the particles. Studies of doxorubicin and epirubicin encapsulated in PEG-phospholipids for decreasing tumor size and growth showed that the encapsulated drugs had a much longer half-life than free drug and are cleared much more slowly from the circulation (for PEG-phospholipid encapsulated doxorubicin, the distribution half-life was about 42 hours, in contrast to the distribution half-life of about 5 minutes for free doxorubicin). The '662 Patent; Mayhew et al., *Int. J.*

Cancer, 51:302-309 (1992); Huang et al., *Cancer Res.*, 52:6774-6781 (1992); and Gabizon et al., "A Pilot Study of Doxorubicin Encapsulated in Long-Circulating (Stealth[®]) Liposomes (S-Dox) In Cancer Patients," *Proc. Am. Soc. Clin. Oncol.* 11:124 (1992).

Similarly, Yuda et al. describe prolongation of the *in vivo* circulation time of PEG-derivatized lipids, such as PEG-derivatized cholesterol, PEG-derivatized succinate, PEG-derivatized phosphatides, and PEG-derivatized glycerols. The results showed that incorporation of the PEG-derivatives into liposomes appreciably increased the blood level of liposomes and correspondingly decreased the RES uptake after injection. Conventional liposomes without PEG showed low blood levels and high accumulation in the liver and spleen, suggesting that these liposomes were readily taken up by the RES. Yuda et al. at 1349.

2. PEG-Derivatized Lipid Drug Carriers Result in Decreased Toxicity of the Administered Drug

In addition to the prolonged half-life of drugs when encapsulated in PEG-derivatized lipids, it was also determined that toxicity of the administered drug is reduced compared to that observed with administration of free drug in animals. This reduction in toxicity is likely because the PEG-liposome carrier prevents a large post-administration spike in plasma levels. Mayhew et al., *Int. J. Cancer*, 51:302-309 (1992).

20

3. PEG-Derivatized Lipid Drug Carriers Result in Increased Stability of the Administered Drug

Another way in which long-circulating PEG-lipids may enhance cytotoxic cell delivery is by protecting drugs that rapidly degrade from contact with plasma for prolonged periods. For example, in a study of mice bearing leukemia tumors, ARA-C (an unstable drug) encapsulated in PEG-derivatized phospholipids was more effective at lower doses in prolonging survival time of mice than was free ARA-C or ARA-C entrapped in conventional liposomes. Allen et al., *Cancer Res.*, 52:2431-2439 (1992). The superiority of the PEG-derivatized phospholipid delivery system to other drug

delivery systems at low doses was attributed to the greatly extended circulation time of the PEG-derivatized lipids, as well as to slow leakage rates of the drug from the carrier.

* * * *

5 There is a need in the art for nanoparticulate compositions of poorly soluble drugs having potentially long blood pool residence times, decreased toxicity, and increased stability to increase the effectiveness of the administered drug, and for methods of making such compositions. In addition, there is a need in the art for a surface stabilizer useful in preparing nanoparticulate compositions of drugs, in which prior known surface stabilizers are ineffective. The present invention satisfies these needs.

10

SUMMARY OF THE INVENTION

The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one PEG-derivatized phospholipid ("PEG-phospholipid"), PEG-derivatized cholesterol ("PEG-cholesterol"), PEG-derivatized cholesterol derivative ("PEG-cholesterol derivative"), PEG-derivatized vitamin A ("PEG-vitamin A"), or PEG-derivatized vitamin E ("PEG-vitamin E") surface stabilizer adsorbed to the surface of the drug. Because of the stability of PEG-lipids, drug/PEG-lipid nanoparticulate compositions afford enhanced blood pool residence times, decreased toxicity, and increased stability of an administered drug

20 Another aspect of the invention is directed to pharmaceutical compositions comprising a nanoparticulate composition of the invention. The pharmaceutical composition preferably comprises a poorly soluble drug, at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed to the surface of the drug, and a pharmaceutically acceptable carrier, as well as any desired excipients.

25 This invention further discloses a method of making a nanoparticulate composition having at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed on the surface of the drug. Such a method comprises contacting a poorly soluble nanoparticulate drug with at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-

vitamin A, or PEG-vitamin E surface stabilizer for a time and under conditions sufficient to provide a nanoparticle/PEG-lipid composition. The PEG-lipid surface stabilizers can be contacted with the drug either before, during, or after size reduction of the drug.

5 The present invention is further directed to a method of treatment comprising administering to a mammal in need a therapeutically effective amount of a nanoparticulate drug/PEG-lipid composition according to the invention.

10 Both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.

BRIEF DESCRIPTION OF THE FIGURES

15 Figure 1a: Shows a photomicrograph of a composition of 2% Compound A and 0.5% albumin following milling;

Figure 1b: Shows a photomicrograph of a composition of 2% Compound A and 1.0% Chremophor EL following milling;

Figure 1c: Shows a photomicrograph of a composition of 2% Compound A and 1.0% F108 following milling;

20 Figure 1d: Shows a photomicrograph of a composition of 2% Compound A and 1.0% F108 in dextrose following milling;

Figure 2a: Shows a photomicrograph of a composition of 2% Compound A, 1.0% F108, and 0.005% DOSS following milling;

25 Figure 2b: Shows a photomicrograph of a composition of 2% Compound A and 1.0% F108 in saline following milling;

Figure 2c: Shows a photomicrograph of a composition of 2% Compound A and 1.0% HPC-SL following milling;

Figure 2d: Shows a photomicrograph of a composition of 2% Compound A and 1.0% tyloxapol following milling;

Figure 3a: Shows a photomicrograph of a composition of 2% Compound A and 1.0% vitamin E PEG following milling;

5 Figure 3b: Shows a photomicrograph of a composition of 2% Compound A and 1.0% PEG-5000 phospholipid in saline following milling;

Figure 3c: Shows a photomicrograph of a composition of 2% Compound A and 1.0% PVP C-15 following milling;

10 Figure 3d: Shows a photomicrograph of a composition of 2% Compound A and 2.0% Tween 80 following milling;

Figure 4: Shows a photomicrograph of a stable nanoparticulate composition of 2% Compound A and 1.0% PEG-5000 phospholipid following milling;

Figure 5: Shows a Horiba particle size analysis of a milled mixture of 2% Compound B and 2% Pluronic F68TM;

15 Figure 6: Shows a Horiba particle size analysis of a milled mixture of 2% Compound B and 2% Pluronic F88TM;

Figure 7: Shows a Horiba particle size analysis of a milled mixture of 1% Compound B and 1% Pluronic F108TM;

20 Figure 8: Shows a Horiba particle size analysis of a milled mixture of 1% Compound B and 0.25% Chremophor ELTM;

Figure 9: Shows a Horiba particle size analysis of a milled mixture of 1% Compound B and 0.25% Tween 80TM;

Figure 10: Shows a photomicrograph of a composition of 2% Compound B and _____ 2% Tyloxapol following milling; and

25 Figure 11: Shows a Horiba particle size analysis of a milled mixture of 2% Compound B and 1% PEG-5000 Phospholipid.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a composition comprising nanoparticulate drug having at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed on the surface thereof, and methods of making and using such nanoparticulate compositions.

A. Compositions

The compositions of the invention comprise nanoparticulate drug and at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed to the surface of the drug. Surface stabilizers useful herein physically adhere to the surface of the nanoparticulate drug, but do not chemically react with the drug or itself. Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.

The present invention also includes nanoparticulate compositions having at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed on the surface thereof, formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for parenteral injection, oral administration in solid or liquid form, rectal or topical administration, and the like.

1. Drug Particles

The nanoparticles of the invention comprise a therapeutic or diagnostic agent, collectively referred to as a "drug." A therapeutic agent can be a pharmaceutical agent, including biologics such as proteins, peptides, and nucleotides, or a diagnostic agent, such as a contrast agent, including x-ray contrast agents. The drug exists either as a discrete, crystalline phase, or as an amorphous phase. The crystalline phase differs from a non-crystalline or amorphous phase which results from precipitation techniques, such as those described in EP Patent No. 275,796.

The invention can be practiced with a wide variety of drugs. The drug is preferably present in an essentially pure form, is poorly soluble, and is dispersible in at least one liquid medium. By "poorly soluble" it is meant that the drug has a solubility in the liquid dispersion medium of less than about 10 mg/mL, and preferably of less than 5 about 1 mg/mL.

The drug can be selected from a variety of known classes of drugs, including, for example, proteins, peptides, nucleotides, anti-obesity drugs, nutriceuticals, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, 10 antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic 15 agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunochemical agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and 20 anoretics, sympathomimetics, thyroid agents, vasodilators and xanthines.

A description of these classes of drugs and a listing of species within each class can be found in Martindale, *The Extra Pharmacopoeia*, Twenty-ninth Edition (The Pharmaceutical Press, London, 1989), specifically incorporated by reference. The drugs are commercially available and/or can be prepared by techniques known in the art.

25

2. PEG-lipid Surface Stabilizers

Suitable PEG-lipid surface stabilizers can preferably be selected from any PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.

5 The molecular weight of the PEG substituent on the lipid affects the circulation half life of the compound. Derivatized lipids having a PEG of high molecular mass, such as about 4000 to about 5000 Da, have long circulation half lives, with lower molecular weights of 2000 Da also being useful. Derivatized lipids having lower PEG
218; and Yuda et al. at 1349.

10 Liposomes containing PEG-derivatives and having functional groups at their terminals, such as DPP-PEG-OH and DSPE-PEG-COOH (e.g., α -(dipalmitoyl-phosphatidyl)- ω -hydroxypolyoxyethylene and distearoylphosphatidyl-N-(3-carboxypropionyl polyoxyethylene succinyl)ethanolamine), also lengthen the circulation half-life of the compounds as compared to non-PEG derivatized compounds and PEG-derivatized compounds of the same molecular weight lacking the functional end group. Yuda et al. at 1349. Moreover, PEG-derivatized compounds having terminal end
15 functional groups and lower molecular weights, e.g., about 1000 Da or less, result in longer circulation times as compared to non-PEG derivatized compounds and PEG-derivatized compounds of the same molecular weight lacking the functional end group

Two exemplary commercially available PEG-liposomes are PEG-5000TM and PEG-2000TM (Shearwater Polymers, Inc.).

20 Two or more surface stabilizers can be used in combination.

3. Auxiliary Surface Stabilizers

25 The compositions of the invention can also include one or more auxiliary surface stabilizers in addition to the at least one PEG-lipid surface stabilizer. Suitable auxiliary surface stabilizers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic and ionic surfactants. Two or more surface auxiliary stabilizers can be used in combination.

Representative examples of auxiliary surface stabilizers include cetyl pyridinium chloride, gelatin, casein, lecithin (phosphatides), dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80®(ICI Specialty Chemicals)); polyethylene glycols (e.g., Carbowaxs 3350® and 1450®, and Carbopol 934® (Union Carbide)), dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, 5 colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, 10 polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68® and F108®, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from 15 sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); a charged phospholipid such as dimyristoyl phophatidyl glycerol, dioctylsulfosuccinate (DOSS); Tetronic 1508®(T-1508) (BASF Wyandotte Corporation), dialkylesters of sodium sulfosuccinic acid (e.g., Aerosol OT®, which is a dioctyl ester of sodium sulfosuccinic acid (American Cyanamid)); Duponol P®, 20 which is a sodium lauryl sulfate (DuPont); Tritons X-200®, which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-110®, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isobutylphenoxy-poly-(glycidol), also known as Olin-LOG® or Surfactant 10-G®(Olin Chemicals, Stamford, CT); Crodestas SL-40®(Croda, Inc.); decanoyl-N-methylglucamide; n-decyl β-D-glucopyranoside; n-decyl β-D-maltopyranoside; n-dodecyl β-D-glucopyranoside; n-dodecyl β-D-maltoside;

heptanoyl-N-methylglucamide; n-heptyl- β -D-glucopyranoside; n-heptyl β -D-thioglucoside; n-hexyl β -D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl β -D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl- β -D-glucopyranoside; octyl β -D-thioglucopyranoside; and the like.

5 Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the *Handbook of Pharmaceutical Excipients*, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 1986), specifically incorporated by reference. The surface stabilizers are commercially available and/or can be prepared by techniques

10 known in the art.

3. Nanoparticulate Drug/PEG-Lipid Particle Size

Preferably, the compositions of the invention contain nanoparticles which have an effective average particle size of less than about 1000 nm (*i.e.*, 1 micron), more preferably less than about 600 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods. By "an effective average particle size of less than about 1000 nm" it is meant that at least 50% of the drug particles have a weight average particle size of less than about 1000 nm when measured by light scattering techniques. Preferably, at least 70% of the drug particles have an average particle size of less than about 1000 nm, more preferably at least 90% of the drug particles have an average particle size of less than about 1000 nm, and even more preferably at least about 95% of the particles have a weight average particle size of less than about 1000 nm.

4. Concentration of Nanoparticulate Drug and Stabilizer

25 The relative amount of drug and one or more surface stabilizers can vary widely. The optimal amount of the surface stabilizers can depend, for example, upon the particular active agent selected, the hydrophilic lipophilic balance (HLB), melting point,

and water solubility of the PEG-lipid surface stabilizer, and the surface tension of water solutions of the stabilizer, *etc.*

The concentration of the one or more surface stabilizers can vary from about 0.1 to about 90%, and preferably is from about 1 to about 75%, more preferably from about 10 to about 60%, and most preferably from about 10 to about 30% by weight based on the total combined weight of the drug substance and surface stabilizer.

The concentration of the drug can vary from about 99.9% to about 10%, and preferably is from about 99% to about 25%, more preferably from about 90% to about 40%, and most preferably from about 90% to about 70% by weight based on the total combined weight of the drug substance and surface stabilizer.

B. Methods of Making Nanoparticulate Formulations

The nanoparticulate drug compositions can be made using, for example, milling or precipitation techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent.

1. Milling to obtain Nanoparticulate Drug Dispersions

Milling of aqueous drug to obtain a nanoparticulate dispersion comprises dispersing drug particles in a liquid dispersion medium, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the drug to the desired effective average particle size. The particles can be reduced in size in the presence of at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer. Alternatively, the particles can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the drug/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode. The resultant nanoparticulate drug dispersion can be utilized in solid or liquid dosage formulations.

2. Precipitation to Obtain Nanoparticulate Drug Compositions

Another method of forming the desired nanoparticulate composition is by microprecipitation. This is a method of preparing stable dispersions of drugs in the presence of one or more surface stabilizers and one or more colloid stability enhancing

surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example: (1) dissolving the drug in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer to form a clear solution; and (3) precipitating the formulation from step 5 (2) using an appropriate non-solvent. The method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means. The resultant nanoparticulate drug dispersion can be utilized in solid or liquid dosage formulations.

10 **C. Methods of Using Nanoparticulate Drug
Formulations Comprising One or More Surface Stabilizers**

The nanoparticulate compositions of the present invention can be administered to humans and animals either orally, rectally, parenterally (intravenous, intramuscular, or subcutaneous), intracisternally, intravaginally, intraperitoneally, locally 15 (powders, ointments or drops), or as a buccal or nasal spray.

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, 20 solvents, or vehicles including water, ethanol, polyols (propylene glycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

25 The nanoparticulate compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged

absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with 5 at least one of the following: (a) one or more inert excipients (or carrier), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, 10 alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as cetyl alcohol and glycerol monostearate; (i) adsorbents, such as kaolin and bentonite; and (j) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. For 15 capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary 20 emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.

25 Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Actual dosage levels of active ingredients in the nanoparticulate 30 compositions of the invention may be varied to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and

method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered drug, the desired duration of treatment, and other factors.

The total daily dose of the compounds of this invention administered to a host in single or divided dose may be in amounts of, for example, from about 1 nanomol to about 5 micromoles per kilogram of body weight. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, potency of the administered drug, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

* * * * *

The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available document, including a U.S. patent, are specifically incorporated by reference.

20

Example 1

The purpose of this example was to test the effectiveness of different conventional intravenous surface stabilizers in producing a stable non-agglomerated nanoparticulate composition of Compound A, a poorly water-soluble compound having therapeutic activity.

All of the following formulations (except for the formulation of Pluronic F108™ and 0.005% DOSS) were prepared for roller milling in a 15 ml amber colored bottle filled with 7.5 ml of 0.8 mm YTZ Zirconia media on a U.S. Stoneware mill.

The Pluronic F108™, HPC-SL, tyloxapol, and PVP formulations were milled for 7 days; the albumin, PEG-vitamin E, Pluronic F108™ in saline, PEG-5000

phospholipid in saline, and Chremophor EL™ formulations were milled for 5 days; the Tween 80™ formulation was milled for 4 days; and the Pluronic F108™ in dextrose formulation was milled for 8 days. The formulation of Pluronic F108™ and 0.005% DOSS was DC milled rather than roller milled (DC milling is higher energy than roller milling) in a 15 ml polycarbonate tube with 4 ml of 0.5 mm SDy-20 polymeric media for 22 hours.

The figures referenced for each composition show a photomicrograph of the composition following milling.

- (a) a mixture of 2% Compound A and 0.5% albumin (Figure 1a);
- (b) a mixture of 2% Compound A and 1.0% Chremophor EL™ (polyoxyethylated castor oil; BASF Corp.) (Figure 1b);
- (c) a mixture of 2% Compound A and 1.0% Pluronic F108™ (a polyoxyethylene-polyoxypropylene copolymer; BASF Corp.) (Figure 1c);
- (d) a mixture of 2% Compound A and 1.0% Pluronic F108™ in dextrose (Figure 1d);
- (e) a mixture of 2% Compound A, 1.0% Pluronic F108™, and 0.005% DOSS (dioctyl sulfosuccinate; Aldrich Chemicals, Inc.) (Figure 2a);
- (f) a mixture of 2% Compound A and 1.0% Pluronic F108™ in saline (Figure 2b);
- (g) a mixture of 2% Compound A and 1.0% hydroxypropyl cellulose (HPC-SL; Nisso Chemical) (Figure 2c);
- (h) a mixture of 2% Compound A and 1.0% tyloxapol (Nycomed) (Figure 2d);
- (i) a mixture of 2% Compound A and 1.0% vitamin E PEG (vitamin E polyethylene glycol; Eastman Chemical, Rochester, NY) (Figure 3a);
- (j) a mixture of 2% Compound A and 1.0% PEG-5000 phospholipid (Shearwater Polymers, Inc) in saline (Figure 3b);
- (k) a mixture of 2% Compound A and 1.0% Plasdone C-15™ (polyvinylpyrrolidone; GAF Corp.) (Figure 3c); and

(l) a mixture of 2% Compound A and 2.0% Tween 80TM (oleate of a polyoxyethylenated sorbitan; ICI Americas Inc., Wilmington, Del.) (Figure 3d).

As evidenced by the photomicrographs of the compositions following 5 milling, none of the surfactants resulted in a stable non-agglomerated nanoparticulate composition of Compound A.

Example 2

The purpose of this example was to test the effectiveness of a PEG-lipid as 10 an intravenously-acceptable surface stabilizer for nanoparticulate compositions. The active agent tested was Compound A.

A mixture of 2% Compound A and 1% PEG-5000TM phospholipid (Shearwater Polymers, Inc.) was roller milled in a 15 ml amber colored bottle filled with 7.5 ml of 0.8 mm YTZ Zirconia media on a U.S. Stoneware mill for 8 days. As shown in 15 Figure 4, a stable nanoparticulate formulation of Compound A was produced. The final effective average particle size of the nanoparticulate dispersion was about 277 nm, with a standard deviation of about 87 nm. In addition, the resultant nanoparticulate formulation was stable over an extended period of time, *i.e.*, for at least one week at room temperature.

20

Example 3

The purpose of this example was to determine the effectiveness of various 25 intravenous (IV)-acceptable surface stabilizers, including PEG-lipids, for nanoparticulate compositions. The active agent used was Compound B, a poorly water-soluble pharmaceutically active compound. Compound B, which serves as a dimerizing agent capable of homodimerizing two proteins containing the FKBP domain in a variety of cellular and extracellular contexts, is intended to be used in the treatment of graft versus host disease (GvHD).

Compositions (a), (b), (d), (e), (f), and (g) below were prepared for roller milling in a 15 ml amber colored bottle filled with 7.5 ml of 0.8 mm YTZ Zirconia media on a U.S. Stoneware mill. The compositions were milled for the following time periods: (a) 132 hours; (b) 2 weeks; (d) 86 hours; (e) 86 hours; (f) 74 hours; and (g) 127 hours.

5 Compositions (c) and (h) were prepared using the higher energy DC mill in a 15 ml polycarbonate tube filled with 4 ml of 0.5 mm polymeric media. Compositions (c) and (h) were milled for 24 and 20 hours, respectively.

The figures referenced for each composition show a Horiba particle size distribution profile or a micrograph (optical microscopy) of the milled composition.

10 (a) a mixture of 2% Compound B and 2% Pluronic F68™ (a polyoxyethylene propylene glycol monofatty acid ester; BASF Corp.) (Figure 5);

(b) a mixture of 2% Compound B and 2% Pluronic F88™ (a polyoxyethylene-polyoxypropylene copolymer; BASF Corp.) (Figure 6);

(c) a mixture of 1% Compound B and 1% Pluronic F108™ (BASF Corp.)

15 (Figure 7);

(d) a mixture of 1% Compound B and 0.25% Cremophor EL™ (Figure 8);

(e) a mixture of 1% Compound B and 0.25% Tween 80™ (Figure 9);

(f) a mixture of 2% Compound B and 1% PVP C-15; this composition solubilized and, therefore, a colloidal suspension was not formed;

20 (g) a mixture of 2% Compound B and 2% tyloxapol; this composition formed large particles (Figure 10); and

(h) a mixture of 2% AP1903 and 1% PEG-5000 Phospholipid (Figure 11).

Figures 5-10 show that the use of Pluronic F68™, Pluronic F88™, 25 Pluronic F108™, Cremophor EL™, Tween 80™, and tyloxapol, produced heterogeneous dispersions, with particle sizes ranging from 1 micron (1000 nm) to 10 microns. Moreover, the minimum particle size obtained was between 300 to 350 nm. In addition, an aggressive milling period was required to obtain small particle sizes with these surface stabilizers.

In contrast, the use of a PEG-lipid surface stabilizer enabled a shorter milling period and produced a well-dispersed colloidal suspension having a maximum particle size of less than about 195 nm. *See e.g.*, Figure 11.

5

* * * *

It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come 10 within the scope of the appended claims and their equivalents.

We claim:

1. A nanoparticulate composition comprising an organic drug having at least one polyethylene glycol-derivatized lipid (PEG-lipid) adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm, wherein the PEG-lipid is selected from the group consisting of a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.

2. The composition of claim 1, wherein the drug is present in an amount of about 99.9 to about 10% (w/w).

3. The composition of claim 1, wherein the at least one PEG-lipid is present in an amount of about 0.1 to about 90% (w/w).

4. The composition of claim 1, wherein the drug is selected from the group consisting of a crystalline phase drug and an amorphous phase drug.

5. The composition of claim 1, further comprising at least one surface stabilizer which is not a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.

6. The composition of claim 1, comprising two or more PEG-lipids selected from the group consisting of PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.

25 7. An injectable formulation comprising the composition of claim 1.

8. The composition of claim 1, wherein the effective average particle size of the nanoparticulate composition is less than about 600 nm.

9. The composition of claim 1, wherein the effective average particle size of the nanoparticulate composition is less than about 400 nm.

10. The composition of claim 1, wherein the effective average particle size of 5 the nanoparticulate composition is less than about 300 nm.

11. The composition of claim 1, wherein the effective average particle size of the nanoparticulate composition is less than about 200 nm.

10 12. The composition of claim 1, wherein the effective average particle size of the nanoparticulate composition is less than about 100 nm.

13. The composition of claim 1, wherein the effective average particle size of the nanoparticulate composition is less than about 50 nm.

15 14. A method of making a nanoparticulate composition comprising an organic drug having at least one polyethylene glycol-derivatized lipid (PEG-lipid) adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm,

20 said method comprising contacting said drug with at least one PEG-lipid for a time and under conditions sufficient to provide a nanoparticle/PEG-lipid composition, wherein the PEG-lipid is selected from the group consisting of a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.

25 15. The method of claim 14, wherein the drug is present in an amount of about 99.9 to about 10% (w/w).

16. The method of claim 14, wherein the at least one PEG-lipid is present in an amount of about 0.1 to about 90% (w/w).

17. The method of claim 14, wherein the drug is selected from the group consisting of a crystalline phase drug and an amorphous phase drug.

18. The method of claim 14, further comprising at least one surface stabilizer
5 which is not a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.

19. The method of claim 14, comprising two or more PEG-lipids selected from the group consisting of PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative,
10 PEG-vitamin A, and PEG-vitamin E.

20. The method of claim 14, wherein the effective average particle size of the nanoparticulate composition is selected from the group consisting of less than about 600 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than
15 about 100 nm, and less than about 50 nm.

21. A method of using a nanoparticulate composition comprising an organic drug having at least one polyethylene glycol-derivatized lipid (PEG-lipid) adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of
20 less than about 1000 nm, comprising administering to a mammal in need a therapeutically effective amount of the drug/PEG-lipid nanoparticulate composition, wherein the PEG-lipid is selected from the group consisting of a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.

25 22. The method of claim 21, wherein the effective average particle size of the nanoparticulate composition is selected from the group consisting of less than about 600 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, and less than about 50 nm.

Figure 1a

2% Compound A + 0.5% Albumin



Figure 1b

2% Compound A + 1% Cremphor EL




Figure 1c

2% Compound A + 1% F108




Figure 1d

2% Compound A + 1% F108 in dextrose




Figure 2a
2% Compound A + 1% F108 + 0.005% DOSS




Figure 2b
2% Compound A + 1% F108 in saline




Figure 2c
2% Compound A + 1% HPC-SL




Figure 2d
2% Compound A + 1% Tyloxapol




Figure 3a
2% Compound A + 1% Vitamin E PEG




Figure 3b
2% Compound A + 1% PEG-5000 Phospholipid in saline




Figure 3c
2% Compound A + 1% PVP C-15




Figure 3d
2% Compound A + 2% Tween 80



Figure 4

2% Compound A + 1% PEG-5000 Phospholipid



Figure 5

2% Compound B and 2% F68

Condition : T% (H₂-No) : 94.3% (LAMP) : 93.5%
 Dist. Form: Std. Form: 1.20-0.101 (R.R. Index : OFF(30), U.sonic : OFF(30))

Agitation : 2 Circuit : 2 U.sonic : OFF(30)

Format : Volume Scaling : Auto Axis : Logx - Linear

Dist. base : Volume Data : Median : 9.388μm SP.Area: 23160cm²/cm³ S.D. : 10.248μm

Mode : 14.174μm Mean : 11.814μm

C.V. : 88.23%

Span : (D 10.0-D 90.0) / D50 = 2.597

Dia. on % (80.0%) : 25.289μm % on Dia.(0.400μm) : 3.3%
 Dia. on % (50.0%) : 9.388μm % on Dia.(0.300μm) : 1.4%
 Dia. on % (95.0%) : 31.809μm % on Dia.(0.200μm) : 0.2%
 Dia. on % (80.0%) : 18.812μm % on Dia.(0.100μm) : 0.0%
 Dia. on % (70.0%) : 14.080μm % on Dia.(1.000μm) : 11.0%




Figure 6

2% Compound B and 2% F88

Condition : T% (He-Ne) : 88.1% (LAMP) : 89.1%
 R.R. Index: 1.26-0.101 Sampling times : 15,
 Agitation : 2 Circuit : 2 U.sonics : ON (30)
 Format Dist.base : Volume Scaling : Auto Axis : LogX - Linear
 Data Median : 0.401 μm SP.Area: 151231 cm^2/am^2 S.D. : 0.581 μm
 Mode : 0.382 μm Mean : 0.586 μm
 C.V. : 98.14%

Span : (D 10.0-D 80.0) / D50 = 2.339

Dia. on % (90.0%)	1.190 μm	% on Dia.(0.400 μm)	49.8%
Dia. on % (50.0%)	0.401 μm	% on Dia.(0.300 μm)	21.7%
Dia. on % (95.0%)	1.881 μm	% on Dia.(0.200 μm)	3.0%
Dia. on % (80.0%)	0.855 μm	% on Dia.(0.100 μm)	0.0%
Dia. on % (70.0%)	0.518 μm	% on Dia.(1.000 μm)	87.8%




Figure 7

1% Compound B and 1% F108

Condition T% (He-Ne):	88.0%	Dist. Form:	Std. R.R. Index	Sampling times :	15
(LAMP):	84.1%		1.20-0.101)
Agitation	: 2	Circuitn	: 2	U.sonic	: OFF(30)
Format				Axis : LogX - LinearY	
Dist.base	: Volume	Scaling	: Auto		
Data					
Median	: 0.317 μ m	SP.Area:	190757 μ m ² /cm ²	S.D.	: 0.227 μ m
Mode	: 0.282 μ m	Mean			
C.V.	: 59.50%				




Figure 8

1% Compound B and 0.25% Chremophor EL




Figure 9

1% Compound B and 0.25% Tween 80

Condition 7% (He-Ne) (LAMP)	98.0%	Dist. Form: R.R. Index	Std. 0.101	Sampling times : 15
Agitation	: 2	Circuits	: 2	Usario : ON (30)
Format Dist. base	: Volume	Scaling	: Auto	Axis : Logx - Linear
Data				
Median	: 2.672 μ m	SP. Area	: 47473 cm^2/cm^2	S.D. : 2.675 μ m
Mode	: 4.172 μ m	Mean	: 3.215 μ m	C.V. : 80.08%





Figure 10

2% Compound B and 2% tyloxapol



Figure 11

2% Compound B and 1% PEG-5000 Phospholipid



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/03676

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/51

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 90 07923 A (CALIFORNIA BIOTECHNOLOGY) 26 July 1990 (1990-07-26) claims 1,6,7 page 11, line 26 -page 12, line 1 page 15, line 5 - line 11 ----	1-6, 14-19,21
A	ISMAILOS, GEORGE; ET AL.: "Enhancement of cyclosporin A solubility by d-alpha-tocopheryl-polyethylene-glycol-100 0 succinate (TPGS)." EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 1, no. 5, 1994, pages 269-271, XP000196248 the whole document ---- -/-	1-22

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

13 July 2000

20/07/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/03676

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 499 299 A (STERLING WINTHROP) 19 August 1992 (1992-08-19) cited in the application the whole document -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/03676

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9007923	A 26-07-1990	US 4994439	A	19-02-1991	
		AU 5087290	A	13-08-1990	
EP 499299	A 19-08-1992	US 5145684	A	08-09-1992	
		AT 184202	T	15-09-1999	
		AU 642066	B	07-10-1993	
		AU 1014592	A	30-07-1992	
		AU 654836	B	24-11-1994	
		AU 1014792	A	30-07-1992	
		CA 2059431	A	26-07-1992	
		CA 2059432	A	26-07-1992	
		DE 69229925	D	14-10-1999	
		DE 69229925	T	17-02-2000	
		EP 0498482	A	12-08-1992	
		ES 2139586	T	16-02-2000	
		FI 920321	A	26-07-1992	
		FI 920322	A	26-07-1992	
		HU 62462	A	28-05-1993	
		HU 60635	A,B	28-10-1992	
		IL 100754	A	16-10-1996	
		IL 100755	A	08-12-1995	
		JP 4317053	A	09-11-1992	
		JP 4295420	A	20-10-1992	
		KR 200061	B	15-06-1999	
		MX 9200291	A	01-10-1992	
		MX 9200292	A	01-10-1992	
		NO 920333	A	27-07-1992	
		NO 303668	B	17-08-1998	
		NZ 241361	A	25-06-1993	
		NZ 241362	A	25-06-1993	
		SG 55104	A	21-12-1998	
		RU 2074002	C	27-02-1997	
		RU 2066553	C	20-09-1996	
		US 5451393	A	19-09-1995	
		US 5494683	A	27-02-1996	
		US 5552160	A	03-09-1996	
		US 5399363	A	21-03-1995	
		US 5318767	A	07-06-1994	